<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00821054</url>
  </required_header>
  <id_info>
    <org_study_id>111582</org_study_id>
    <nct_id>NCT00821054</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients</brief_title>
  <official_title>An Open Label Study to Examine the Effects of Low-Fat and High-Fat Meals on the Pharmacokinetics of Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will be a randomized 3-treatment, cross-over study to evaluate the bioavailability&#xD;
      of lapatinib administered after a high or low-fat meal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 6, 2009</start_date>
  <completion_date type="Actual">March 22, 2011</completion_date>
  <primary_completion_date type="Actual">March 22, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Protocol specified pharmacokinetic parameters</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as assessed by evaluation of adverse events (AEs), changes in laboratory values, and vital signs</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Neoplasms, Breast</condition>
  <arm_group>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A, B or C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A, B or C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A, B or C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>Treatment A: one dose of 1250mg lapatinib 1 hour before starting a low-fat breakfast; Treatment B: one dose of 1250mg lapatinib 1 hour after finishing a low fat breakfast; or Treatment C: one dose of 1250mg lapatinib 1 hour after finishing a high-fat breakfast.</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_label>Period 3</arm_group_label>
    <other_name>TYKERB - US; TYVERB - UK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic, histologically confirmed breast cancer that over-expresses ErbB2 (3+ by&#xD;
             IHC; FISH or CISH positive).&#xD;
&#xD;
          -  Is at least 18 years of age and not greater than 65 years of age.&#xD;
&#xD;
          -  Is male or female. A female is eligible to enter and participate in the study if she&#xD;
             is of:&#xD;
&#xD;
               1. Non-childbearing potential (i.e. physiologically incapable of becoming pregnant),&#xD;
                  including any female who: has had a hysterectomy; has had a bilateral&#xD;
                  oophorectomy (ovariectomy); has had a bilateral tubal ligation, or is&#xD;
                  post-menopausal (a demonstration of total cessation of menses for ≥ 1 year) or in&#xD;
                  questionable cases a blood sample with simultaneous follicle stimulating hormone&#xD;
                  (FSH) &gt; 40 MlU/ml and estradiol &lt; 40 pg/ml (&lt;140 pmol/L) is confirmatory.&#xD;
&#xD;
               2. Childbearing potential, has a negative serum pregnancy test at Screening and&#xD;
                  agrees to one of the following: double-barrier contraception (condom with&#xD;
                  spermicidal jelly, foam, suppository, or film; diaphragm with spermicide; or male&#xD;
                  condom and diaphragm); complete abstinence from sexual intercourse from two weeks&#xD;
                  prior to administration of the study drug, throughout the active study treatment&#xD;
                  period; vasectomized partner who is sterile prior to the female subject's entry&#xD;
                  and is the sole sexual partner for that female.&#xD;
&#xD;
          -  Is able to swallow and retain oral medication.&#xD;
&#xD;
          -  ECOG performance status 0 to 2.&#xD;
&#xD;
          -  Adequate bone marrow function.&#xD;
&#xD;
          -  Hemoglobin ≥ 9 gm/dL.&#xD;
&#xD;
          -  Absolute granulocyte count ≥1,500/mm3 (1.5 x 109/L).&#xD;
&#xD;
          -  Platelets ≥ 75,000/mm3 (75 x 109/L).&#xD;
&#xD;
          -  Calculated creatinine clearance (CrCl) ≥ 50 ml/min based on Cockcroft and Gault&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 X upper limit of normal of institutional values and INR ≤ 1.5.&#xD;
&#xD;
          -  Alanine transaminase (ALT) ≤ three times the upper limit of the institutional values&#xD;
             or ≤ five times ULN with documented liver metastases.&#xD;
&#xD;
          -  Has a left ventricular ejection fraction (LVEF) within the normal institutional range&#xD;
             based on ECHO or MUGA.&#xD;
&#xD;
          -  Life expectancy of ≥12 weeks&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is pregnant or lactating.&#xD;
&#xD;
          -  Has malabsorption syndrome, a disease affecting gastrointestinal function, or&#xD;
             resection of the stomach or small bowel.&#xD;
&#xD;
          -  Has current active hepatic or biliary disease (with exception of patients with&#xD;
             Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver&#xD;
             disease per investigator assessment).&#xD;
&#xD;
          -  Has evidence of symptomatic or uncontrolled brain metastases or leptomeningeal&#xD;
             disease. Subjects with brain metastases treated by surgery and/or radiotherapy are&#xD;
             eligible if neurologically stable and do not require steroids or anticonvulsants.&#xD;
&#xD;
          -  Is considered medically unfit for the study by the investigator as a result of the&#xD;
             medical interview, physical exam, or screening investigations.&#xD;
&#xD;
          -  Has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to the investigational product such as gefitinib [Iressa] and&#xD;
             erlotinib [Tarceva].&#xD;
&#xD;
          -  Has received treatment with any investigational drug in the previous four weeks.&#xD;
&#xD;
          -  Has received chemotherapy, immunotherapy, biologic therapy or hormonal therapy for the&#xD;
             treatment of cancer within the past 14 days, with the exception of mitomycin C which&#xD;
             is restricted for the past six weeks.&#xD;
&#xD;
          -  Is receiving any prohibited medication within the timeframe indicated on the&#xD;
             prohibited medication list for this study.&#xD;
&#xD;
          -  Has physiological, familial, sociological, or geographical conditions that do not&#xD;
             permit compliance with the protocol.&#xD;
&#xD;
          -  Has inadequate venous access for protocol-related blood draws.&#xD;
&#xD;
          -  Clinically significant electrocardiogram (ECG) abnormality.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Has consumed red wine, seville oranges, grapefruit or grapefruit juice and/or&#xD;
             kumquats, pummelos, exotic citrus fruit (i.e. star fruit, bitter melon), grapefruit&#xD;
             hybrids or fruit juices from 7 days prior to the first dose of study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>January 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I Food Effect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

